Although it is unknown whether anti-VEGF agents suppress retinal vascularization or not, the prevalence of these vascular abnormalities is due to anti-VEGF therapy or the regression of ROP itself, which remains to be controversial, and the long-term implications are yet not known10. The gene discussed is VEGFA; the disease is retinopathy of prematurity.